 WIXOM, Mich., Aug. 19, 2021 GLOBE NEWSWIRE -- Rockwell Medical, Inc. Nasdaq: RMTI Rockwell Medical or the Company, a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Companys Board of Directors approved the grant of an option to purchase 350,000 shares of the Companys common stock to Megan C. Timmins, the Companys Senior Vice President, General Counsel and Secretary the Inducement Grant. The Inducement Grant has been granted outside of the Companys 2018 Long Term Incentive Plan Plan, but remains subject to the terms and conditions of such Plan. The Inducement Grant was granted as an inducement material to such individuals entering into employment with Rockwell Medical in accordance with Nasdaq Listing Rule 5635c4. 